These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
908 related articles for article (PubMed ID: 33336844)
21. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. Raimondi A; Randon G; Prisciandaro M; Pagani F; Lonardi S; Antoniotti C; Bozzarelli S; Sartore-Bianchi A; Tampellini M; Fanchini L; Murialdo R; Clavarezza M; Zaniboni A; Berenato R; Ratti M; Petrelli F; Antonuzzo L; Giordano M; Rossi A; Di Bartolomeo M; Di Maio M; Pietrantonio F; Morano F Int J Cancer; 2022 Nov; 151(10):1760-1769. PubMed ID: 35678328 [TBL] [Abstract][Full Text] [Related]
22. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial. Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E; ESMO Open; 2020 Nov; 5(6):e000944. PubMed ID: 33148620 [TBL] [Abstract][Full Text] [Related]
23. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. Antoniotti C; Germani MM; Rossini D; Lonardi S; Pietrantonio F; Santini D; Marmorino F; Allegrini G; Daniel F; Raimondi A; Borelli B; Zaniboni A; Conca V; Abraham J; Spetzler D; Maiello E; Boccaccino A; Passardi A; Giordano M; Tamburini E; Korn MW; Masi G; Cremolini C Eur J Cancer; 2022 May; 167():23-31. PubMed ID: 35366570 [TBL] [Abstract][Full Text] [Related]
24. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055 [TBL] [Abstract][Full Text] [Related]
25. Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. Watanabe J; Maeda H; Nagasaka T; Yokota M; Hirata K; Akazawa N; Kagawa Y; Yamada T; Shiozawa M; Ando T; Kato T; Mishima H; Sakamoto J; Oba K; Nagata N Int J Cancer; 2022 Dec; 151(12):2172-2181. PubMed ID: 35723084 [TBL] [Abstract][Full Text] [Related]
26. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015 [TBL] [Abstract][Full Text] [Related]
27. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476 [TBL] [Abstract][Full Text] [Related]
28. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. Battaglin F; Schirripa M; Buggin F; Pietrantonio F; Morano F; Boscolo G; Tonini G; Lutrino ES; Lucchetti J; Salvatore L; Passardi A; Cremolini C; Arnoldi E; Scartozzi M; Pella N; Boni L; Bergamo F; Zagonel V; Loupakis F; Lonardi S BMC Cancer; 2018 Jan; 18(1):98. PubMed ID: 29370781 [TBL] [Abstract][Full Text] [Related]
29. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715 [TBL] [Abstract][Full Text] [Related]
30. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832 [TBL] [Abstract][Full Text] [Related]
31. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Rossini D; Germani MM; Lonardi S; Pietrantonio F; Dell'Aquila E; Borelli B; Allegrini G; Maddalena G; Randon G; Marmorino F; Zaniboni A; Buonadonna A; Boccaccino A; Conca V; Antoniotti C; Passardi A; Masi G; Cremolini C Eur J Cancer; 2022 Jul; 170():64-72. PubMed ID: 35594613 [TBL] [Abstract][Full Text] [Related]
32. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; Ronzoni M; Racca P; Loupakis F; Zaniboni A; Tonini G; Buonadonna A; Marmorino F; Allegrini G; Granetto C; Masi G; Zagonel V; Sensi E; Fontanini G; Boni L; Falcone A Ann Oncol; 2018 Jul; 29(7):1528-1534. PubMed ID: 29873679 [TBL] [Abstract][Full Text] [Related]
33. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C Ann Oncol; 2019 Dec; 30(12):1969-1977. PubMed ID: 31573612 [TBL] [Abstract][Full Text] [Related]
34. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943 [TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218 [TBL] [Abstract][Full Text] [Related]
36. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920 [TBL] [Abstract][Full Text] [Related]
37. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). Kurreck A; Geissler M; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Stintzing S; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Modest DP J Cancer Res Clin Oncol; 2020 Oct; 146(10):2681-2691. PubMed ID: 32449003 [TBL] [Abstract][Full Text] [Related]
38. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335 [TBL] [Abstract][Full Text] [Related]
39. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
40. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]